*Shuhei Wada¹, Kunihiro Iwamoto¹, Masashi Ikeda¹ (1. Department of Psychiatry, Nagoya University Graduate School of Medicine)

*Manabu Saito¹, Ai Terui², Shuji Shimoyama³, Yui Sakamoto², Ayako Osato¹ (1. Department of Clinical Psychological Sciences, Graduate School of Health Sciences, Hirosaki University, 2. Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, 3. Department of Neurophysiology, Graduate School of Medicine, Hirosaki University)

*Benchalak Maneeton¹, Prapinpatch Maneeton², Yanisa Winichaikul³, Suttipong Kawilapat¹, Nongluck Kienngam⁴, Narong Maneeton¹ (1. Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand, 2. Chiang Mai University Demonstration School, Faculty of Education, Chiang Mai University, Chiang Mai 50200, Thailand, 3. Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand., 4. Department of Education Psychology and Guidance Program, Faculty of Education Chiang Mai University, Chiang Mai 50200, Thailand)

*Xiao Liu¹, Ji-tao Li¹, Tian-mei Si¹ (1. Department of Psychopharmacology, Peking University 6th Hospital, Beijing, China)

*Daisuke Hatta¹, Kaito Kanamoto¹, Shiho Makiya¹, Kaori Watanabe¹, Tatsuya Kishino^2,5, Yuki Fuchigami³, Shigeru Kawakami³, Akira Kinoshita^4,5, Koh-ichiro Yoshiura^4,5, Naohiro Kurotaki⁴, Keiro Shirotani^1,5, Nobuhisa Iwata^1,5 (1. Department of Genome-based Drug Discovery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, 2. Division of Functional Genomics, Research Center for Advanced Genomics, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, 3. Department of Pharmaceutical Informatics, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, 4. Department of Human Genetics, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, 5. Leading Medical Research Core Unit, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan)

*Moeka Tanabe^1,2, Kazuo Kunisawa¹, Imari Saito¹, Aika Kosuge¹, Hiroyuki Tezuka³, Tomoki Kawai¹, Masaya Hasegawa¹, Hisayoshi Kubota^1,4, Kuniaki Saito^2,5, Toshitaka Nabeshima^2,6, Akihiro Mouri^1,6 (1. Department of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Health Sciences, Aichi, Japan., 2. Laboratory of Health and Medical Science Innovation, Fujita Health University Graduate School of Health Science, Aichi, Japan., 3. Department of Cellular Function Analysis, Research Promotion Headquarters, Fujita Health University, Aichi, Japan., 4. Division of Behavioral Neuropharmacology, International Center for Brain Science (ICBS), Fujita Health University, Aichi, Japan., 5. Advanced Diagnostic System Research Laboratory, Fujita Health University Graduate School of Health Science, Aichi, Japan., 6. Japanese Drug Organization of Appropriate Use and Research (J-DO), Aichi, Japan.)

*Mikio Yoshida¹, Hikari Katada¹, Yuya Isozumi¹, Shunya Kawai¹, Itaru Kushima², Akira Yoshimi¹, Norio Ozaki³, Yukihiro Noda¹ (1. Division of Clinical Sciences and Neuropsychopharmacology, Meijo University, Faculty and Graduate School of Pharmacy, 2. Department of Psychiatry, Nagoya University, Graduate School of Medicine, 3. Pathophysiology of Mental Disorders, Nagoya University, Graduate School of Medicine)

*Shinobu Hirai¹, Shoko Tamura¹, Hiroko Shimbo¹, Jonghyuk Park¹, Haruo Okado¹ (1. Tokyo Metropolitan Institute of Medical Science (TMiMS))

*Tomoko Tanaka¹, Shinobu Hirai¹, Hiroyuki Manabe², Hiroko Shimbo¹, Hikari Yoshitane¹, Haruo Okado¹ (1. Tokyo Metropolitan Institute of Medical Science, 2. Nara Medical University)

*Misaki Iwahashi^1,2, Takeshi Yoshimura¹, Wakana Harigai¹, Kazuhiro Takuma^2,3, Hitoshi Hashimoto^3,4,5,6,7, Taiichi Katayama¹, Atsuko Hayata-Takano^2,3,4 (1. Department of Child Development and Molecular Brain Science, United Graduate School of Child Development, Osaka University, Osaka, Japan, 2. Department of Pharmacology, Graduate School of Dentistry, Osaka University, Osaka, Japan, 3. Molecular Research Center for Children’s Mental Development, United Graduate School of Child Development, Osaka University, Osaka, Japan, 4. Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan, 5. Transdimensional Life Imaging Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan, 6. Division of Bioscience, Institute for Datability Science, Osaka University, Osaka, Japan, 7. Department of Molecular Pharmaceutical Science, Graduate School of Medicine, Osaka University, Osaka, Japan)